Participant flow

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma · Source last updated 2021-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.

   id

   FG000

   title

   Panobinostat

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         26

      type

      Disease progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Abnormal laboratory value

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         38

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         36

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total 38 participants were enrolled in the study, of which 38 discontinued the study.

recruitment Details

The study was conducted at 27 centers in 6 countries

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice